Sarah Waliany, MD, MS

E4512: adjuvant crizotinib for resected stage II-III ALK+ NSCLC #DavidGerber. Insightful discussion by @JessicaJLinMD #WCLC25
💠Adjuvant crizotinib did not prolong median DFS
💠Biomarkers still critical for early-stage NSCLC given role of TKIs eg. osi (ADAURA) & alectinib (ALINA)

Exciting #ARROS1 phase 1/2 trial results of #zidesamtinib in ROS+ mNSCLC #WCLC25 @alexdrilon
💠Active in heavily pretreated pts: ORR 44% after 1-4 prior ROS1 TKIs; 51% after 1 prior TKI (criz or entrect)
💠Responses after prior repotrectinib & taletrectinib; active against G2032R

Exciting final overall survival analysis of FLAURA2: osi + PT/pem vs osi alone for #EGFRm NSCLC #WCLC25 @dplanchard
💠⬆️OS with osi/CTx (median 47.5 mo) vs osi (37.6 mo)
💠Benefit despite median exposure to pem 8.3 mo & most pts in control arm receiving subsequent PT-based chemo

Enjoyed participating in the session on adjuvant #EGFR & #ALK TKI at Yin & Yang Lung Cancer Masterclass w/ @Tony_Calles & @MarianaBrandao0 w/ important debate on role of adjuvant chemo prior to TKI. Thanks to @mihaela_aldea @RobertoFerrara_ @BRicciutiMD for the chance to present!

Dynamic debate b/w @JuliaRotow & @BenjaminBesseMD on 1L combos vs 1L osi for #EGFR+ NSCLC
💠#FLAURA2 & #MARIPOSA more effective for most subgroups than osi alone: highly important for pts w/⬆️risk features
💠Significant tox of MARIPOSA: need for mitigation (subQ ami, COCOON ppx)